TuisRLF • SWX
add
RELIEF THERAPEUTICS Holding SA
Vorige sluiting
CHF 3,84
Dagwisseling
CHF 3,78 - CHF 3,96
Jaarwisseling
CHF 1,06 - CHF 7,60
Markkapitalisasie
55,60 m CHF
Gemiddelde volume
51,73 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
SWX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CHF) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 2,83 m | 87,03% |
Bedryfskoste | 4,04 m | -41,31% |
Netto inkomste | -2,28 m | 91,93% |
Netto winsgrens | -80,60 | 95,69% |
Wins per aandeel | — | — |
EBITDA | -1,27 m | 74,88% |
Effektiewe belastingkoers | -14,01% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CHF) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 10,73 m | -16,20% |
Totale bates | 70,92 m | -43,61% |
Totale aanspreeklikheid | 21,65 m | -31,07% |
Totale ekwiteit | 49,27 m | — |
Uitstaande aandele | 12,55 m | — |
Prys om te bespreek | 0,98 | — |
Opbrengs op bates | -7,01% | — |
Opbrengs op kapitaal | -9,62% | — |
Kontantvloei
Netto kontantverandering
| (CHF) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -2,28 m | 91,93% |
Kontant van bedrywe | -1,58 m | 69,75% |
Kontant van beleggings | -3,50 k | 96,82% |
Kontant van finansiering | -308,00 k | -114,76% |
Netto kontantverandering | -1,91 m | 40,61% |
Beskikbare kontantvloei | -635,56 k | 75,84% |
Meer oor
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG and listed on the SIX Swiss Exchange in 2016. Wikipedia
Gestig
2013
Webwerf
Werknemers
36
